Countries Request a quote
PT-141 / Oxytocin Spray — Alphagenics spray
Sexual Health

PT-141 / Oxytocin Spray

Bremelanotide + Oxytocin

Combination of a melanocortin agonist and a hypothalamic nonapeptide

Components2
Total5/10mg · 20/20mg
Available presentations
Quote via WhatsApp Quick guide Research protocol View evidence Reconstitution calculator Physician login

About PT-141 / Oxytocin Spray

This spray combines PT-141 (bremelanotide), a melanocortin receptor agonist FDA-approved as a subcutaneous injection for hypoactive sexual desire disorder in premenopausal women, with oxytocin, a hypothalamic nonapeptide studied for its role in bonding and sexual response.

PT-141 has been studied for its central action on desire and arousal; oxytocin for its link to orgasm and contentment afterward.

Quick guide · 5 key points

PT-141 and oxytocin: two peptides combined

This spray pairs PT-141 (bremelanotide), studied for its central action on desire and arousal, with oxytocin, studied for its link to orgasm. Here are five things the research shows.

Open guide (PDF) Download guide
  1. 1

    Two peptides, two receptors, connected pathways

    PT-141 is a non-selective melanocortin receptor agonist; according to the FDA label, MC1R and MC4R are the most relevant at therapeutic doses. Oxytocin acts on its own receptor, OXTR. In mice, MC4R signaling on oxytocin neurons was associated with normal ejaculation, a link between the two systems.1,2,3

    PT-141Central nervous system melanocortin receptors; studied for desire and arousal.
    OxytocinOxytocin receptor (OXTR); studied in the orgasm phase.
    MC4R + OXTRThe main receptor for each component
  2. 2

    PT-141: phase 3 trials in women

    In the two phase 3 RECONNECT trials, in premenopausal women with hypoactive sexual desire disorder, subcutaneous bremelanotide was associated with a significant increase in desire and less distress than placebo. It was FDA-approved in 2019 (Vyleesi®) as a subcutaneous injection for that indication; it is not approved for use in men.4,1

    1,267Women randomized in the two RECONNECT trials
  3. 3

    PT-141: erectile response in men

    In healthy men, subcutaneous PT-141 was associated with significant erectile responses measured by RigiScan®, even without visual sexual stimulation. In men with erectile dysfunction and an inadequate response to 100 mg Viagra®, significant responses versus placebo were also observed.5

    100 mgViagra® dose with an inadequate response in participants
  4. 4

    Oxytocin: it rises during the sexual response

    In a study of 9 healthy men and 13 healthy women, plasma oxytocin rose during arousal and was significantly higher during orgasm than at baseline. The authors link it to smooth muscle contractions of the reproductive tract during orgasm.6

    22Healthy adults in the plasma oxytocin study
  5. 5

    Evidence per component, and side effects

    These studies tested each component on its own, not the combination. In animals, oxytocin facilitates sexual behavior, but human studies have not confirmed this. For bremelanotide, the FDA label describes nausea (40%), flushing and headache, and a transient rise in blood pressure after each dose.7,8,1

    40%Nausea with bremelanotide in phase 3 trials (FDA label)
References
  1. U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557, 2019. Official source
  2. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-83. PMID 11274341
  3. Semple E, et al. Oxytocin Neurons Enable Melanocortin Regulation of Male Sexual Function in Mice. Mol Neurobiol. 2019;56(9):6310-23. PMID 30756300
  4. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840
  5. Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-42. PMID 14999221
  6. Carmichael MS, et al. Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987;64(1):27-31. PMID 3782434
  7. Melis MR, Argiolas A. Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances. Int J Mol Sci. 2021;22(19):10376. PMID 34638719
  8. Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4):qeag078. PMID 42862021

Components per bottle

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

PT-141

5 · 20 mg
AcNleciclo[Asp-His-D-Phe-Arg-Trp-Lys]OH
Molecular formula
C50H68N14O10
Molecular weight
1025.2 g/mol
CAS number
189691-06-3
PubChem CID
9941379
Length
7 aa (cíclico)

Oxitocina

10 · 20 mg
C1Y2I3Q4N5C6P7L8G9-NH2
Molecular formula
C43H66N12O12S2
Molecular weight
1007.2 g/mol
CAS number
50-56-6
PubChem CID
439302
Length
9 aa

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Clinical study

    PT-141: in the phase 3 RECONNECT trials (more than 1,200 premenopausal women with hypoactive sexual desire disorder), an improvement in sexual desire and a reduction in associated distress versus placebo have been shown.

    Kingsberg SA et al. Obstet Gynecol. 2019;134:899-908 · PMID 31599840
  2. Regulatory

    PT-141: bremelanotide has received FDA approval (2019), as a subcutaneous injection, for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

    FDA. Vyleesi (bremelanotide) — prescribing information, NDA 210557
  3. Clinical study

    PT-141: in healthy men and in men with mild-to-moderate erectile dysfunction, intranasal PT-141 has been associated with an erectile response significantly greater than placebo at doses above 7 mg.

    Diamond LE et al. Int J Impot Res. 2004;16:51-59 · PMID 14963471
  4. Clinical study

    Oxytocin: in 29 healthy couples, 24 IU of intranasal oxytocin did not change drive or arousal, but was associated with greater orgasm intensity and greater contentment after intercourse.

    Behnia B et al. Horm Behav. 2014;65:308-318 · PMID 24503174
  5. Review

    Oxytocin: in a review of 38 trials (1,529 participants) using 18–40 IU intranasally in the short term, side effects did not differ from placebo.

    MacDonald E et al. Psychoneuroendocrinology. 2011;36:1114-1126 · PMID 21429671

More in Sexual Health

KisspeptinPT-141Oxytocin